|
| Tuesday, February 27, 2018 |
|
|
Eisai: Launch of "Dementia Support" Insurance to Provide for Dementia in Japan |
| Eisai Co., Ltd. announced that it has jointly developed with Saint-Plus Small Amounts and Short Term Insurance Co., Ltd. dementia diagnosis lump-sum insurance "Dementia Support" in Japan, and that Saint Plus has launched this product today. more info >> |
|
| Wednesday, February 21, 2018 |
|
|
Eisai Certified in 2018 as Outstanding Health and Productivity Management Organization (White 500) |
| Eisai Co., Ltd. announced today that it has been certified in 2018 as an Outstanding Health and Productivity Management Organization in the large enterprise category (White 500) by Japan's Ministry of Economy, Trade and Industry. more info >> |
|
| Friday, February 16, 2018 |
|
|
Eisai: U.K. NICE Recommends Anticancer Agent Lenvima as Treatment for Thyroid Cancer |
| Eisai Co., Ltd. announced today that its in-house developed anticancer agent Lenvima has been recommended by the U.K. NICE as a treatment for progressive, locally advanced or metastatic differentiated thyroid cancer in adults whose disease does not respond to radioactive iodine, in NICE's FAD. more info >> |
|
| Monday, February 12, 2018 |
|
|
Eisai's Phase III Trial Results of Anticancer Agent Lenvatinib in Hepatocellular Carcinoma Published in The Lancet |
| Eisai Co., Ltd. announced that the results of a Phase III study (REFLECT study, Study 304) of its in-house discovered and developed anticancer agent lenvatinib mesylatein patients with hepatocellular carcinoma (HCC) have been published in the online version of The Lancet. more info >> |
|
| Thursday, February 1, 2018 |
|
|
Eisai: Primary Endpoint Met in Phase II / III Clinical Study of Investigational Parkinson's Disease Treatment Safinamide in Japan |
| Eisai Co., Ltd. and Meiji Seika Pharma Co., Ltd. announced today that the primary endpoint was met in a Phase II/III clinical study on the investigational Parkinson's disease treatment ME2125 in patients with Parkinson's disease. more info >> |
|
| Monday, January 22, 2018 |
|
|
Eisai Presents Results of Analysis of Phase III Trial of Lenvima (Lenvatinib) |
| Eisai Co., Ltd. announced today that the results of an analysis of a Phase III trial of its in-house discovered and developed anticancer agent lenvatinib mesylate versus sorafenib. more info >> |
|
| Saturday, January 20, 2018 |
|
|
Eisai: Drug Approval of Bile Acid Transporter Inhibitor "GOOFICE 5mg" Tablet Obtained in Japan |
| Eisai's subsidiary for gastrointestinal disease area EA Pharma Co., Ltd. and Mochida Pharmaceutical Co., Ltd today announced that EA Pharma has obtained new drug approval for bile acid transporter inhibitor "GOOFICE 5mg Tablet" for chronic constipation (excluding structural disease-induced constipation) in Japan. more info >> |
|
| Friday, January 19, 2018 |
|
|
Eisai: Oral Antifungal Agent NAILIN Capsules 100mg Approved in Japan |
| Sato Pharmaceutical Co., Ltd. obtained marketing and manufacturing approval for the oral antifungal agent NAILIN Capsules 100mg containing the active ingredient fosravuconazole L-lysine ethanolate (fosravuconazole) for the treatment of onychomycosis in Japan on January 19, 2018. more info >> |
|
|
Eisai Enters into Licensing Agreement with Adlai Nortye for Potential Anticancer Agent E7046 |
| Eisai Co., Ltd. announced today that it has entered into a licensing agreement granting exclusive rights concerning the research, development, manufacture and marketing of Eisai's in-house discovered potential anticancer agent E7046. more info >> |
|
| Thursday, January 18, 2018 |
|
|
Eisai: Patent Infringement Litigation for Antiemetic Agent ALOXI in the United States |
| Eisai has announced today that the United States Court of Appeals for the Federal Circuit, in the patent infringement lawsuit for antiemetic agent ALOXI (palonosetron hydrochloride) injection has denied Helsinn's petition for rehearing en banc. more info >> |
|
|
|
